Category: Presentation

ASCO 2012: A Phase II Biomarker Assessment of Tivozanib in ONcology trial in patients (pts) with advanced renal cell carcinoma (BATON RCC)

ASCO 2012: Final Results of a Phase Ib Study of Tivozanib and FOLFOX6 in Patients with Advanced Gastrointestinal Tumors

ASCO 2012: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial

AACR 2012: The Effect of Food on the Pharmacokinetics of Tivozanib

AACR-NCI-EORTC 2011: A Phase I Study to Evaluate the Absorption, Metabolism and Excretion of the Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Tivozanib

AACR-NCI-EORTC 2011: A Phase I QTc Study of Tivozanib in Patients with Advanced Solid Tumors

AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade

EMUC 2011 – Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC

ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma